Alex joined SV in 2020 as a Senior Associate in the biotech team, to help form and fund companies developing transformational new medicines. Alex serves as a board observer at Alchemab Therapeutics, EyeBio and TRexBio, three SV created companies.
Alex identifies and evaluates new opportunities and advises portfolio company management on strategy, fundraising, and business development.
Prior to joining SV, Alex led Business Development and Strategy for the Immuno-oncology focused biotech Xilio Therapeutics (f.k.a. Akrevia Therapeutics), including through its $100.5m Series B equity raise. Before joining Xilio Therapeutics in 2018, Alex was a Life Science Specialist Consultant at L.E.K. Consulting in Boston, where he advised investors and executives in the life sciences industry (biotech, pharmaceuticals, diagnostics, and medical devices) on corporate, business unit, franchise and product strategic decisions.
Before joining L.E.K. Consulting, Alex was a Postdoctoral Fellow in Dr Dan Barouch’s lab at Harvard Medical School, where he developed novel immunotherapies for cancers and HIV-1. He has authored over a dozen scientific publications (Nature, Science Immunology, Journal of Immunology), and was part of the team to develop the world’s first Zika virus vaccine in response to the 2016 epidemic.
Outside of SV, Alex sits on the Cancer Research UK Seed Investment Committee and in his free time, enjoys spending time with his family, listening to The Beatles, and indulging in Viennese coffee houses.
Alex received his MRes and PhD in Medicine (Immunology) from Imperial College London, and holds a BA (Hons) in Biological Sciences from Christ Church, University of Oxford.